PhRMA CEO: Ubl Pick Brings User Fee, Reimbursement Expertise
Steve Ubl has led AdvaMed for 10 years, raising profile of device industry on Capitol Hill and executing well-regarded public relations campaign of the kind the drug industry might need as it enters political maelstrom on pricing.
You may also be interested in...
A scientist may provide a certain look, but understanding politics is more important to ensuring the health of the pharma industry, the outgoing president and CEO of BIO said in an interview.
Long-time CEO of the Biotechnology Innovation Organization will remain until after the 2020 election and help with the leadership transition.
Recently installed CEO Stephen Ubl presents policy solutions as industry’s best response to ongoing public criticism over high drug prices.